Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Saimeng Shi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5057607133. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2022: 2 papers · 2023: 4 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Neuro-tumor-immune crosstalk in pancreatic cancer: Mechanisms and therapeutic insights. Last author DOI 10.1016/j.bbcan.2026.189575↗
  2. Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation. First author DOI 10.1186/s13046-025-03563-9↗
  3. The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2024.09.032↗
  4. Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway. Co-author DOI 10.3724/abbs.2023286↗
  5. Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1002/ijc.34468↗
  6. Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2023.216411↗
  7. Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer. Co-author DOI 10.1038/s41419-023-06313-x↗
  8. Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/febs.16879↗
  9. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
  10. Innate immunity in pancreatic cancer: Lineage tracing and function. First author DOI 10.3389/fimmu.2022.1081919↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Long‐Yun Ye · 9 shared papers, 2022–2025 · strength 1.77
  2. Kaizhou Jin · 8 shared papers, 2022–2025 · strength 1.51
  3. Weiding Wu · 7 shared papers, 2022–2024 · strength 1.28
  4. Xianjun Yu · 7 shared papers, 2022–2024 · strength 1.28
  5. Qinglin Fei · 7 shared papers, 2022–2025 · strength 1.26
  6. Duancheng Guo · 5 shared papers, 2023–2026 · strength 1.20
  7. Zhenyu Liao · 4 shared papers, 2022–2023 · strength 0.62
  8. Tianjiao Li · 4 shared papers, 2022–2023 · strength 0.62
  9. Huiru Zhang · 3 shared papers, 2022–2023 · strength 0.46
  10. Jianguo Jin · 1 shared paper, 2026 · strength 0.32
  11. Xuan Lin · 2 shared papers, 2022–2023 · strength 0.30
  12. Wei Chen · 1 shared paper, 2022 · strength 0.26
  13. Jianhui Yang · 1 shared paper, 2025 · strength 0.23
  14. Weiding Wu · 1 shared paper, 2025 · strength 0.23
  15. Wei Chen · 1 shared paper, 2023 · strength 0.16
  16. Hao Li · 1 shared paper, 2022 · strength 0.13
  17. Zhiwen Xiao · 1 shared paper, 2022 · strength 0.13
  18. Huaxiang Xu · 1 shared paper, 2022 · strength 0.13
  19. Liang Liu · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.